Innovating Works
NMP-29-2015
NMP-29-2015: Increasing the capacity to perform nano-safety assessment
Scope:Specific challenge: Systems biology, high throughput screening and toxicogenomics approaches have the potential to revolutionise how chemical substances, including nanomaterials, are assessed for regulatory and risk management purposes. A paradigm shift in toxicology using innovative techniques such as High Thoughput Screening (HTS) approaches, Toxicogenomics and High Content Analysis (HCA) is being established. With such approaches it is possible to identify underlying affected pathways (so called ‘toxicity pathways’). The challenge is to develop and demonstrate a mechanism-based understanding of toxicity, which will enable improved toxicity testing by identifying novel endpoints essential to tailor-made first tier hazard and risk assessment of novel and emerging materials.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 26-03-2015.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Scope:Specific challenge: Systems biology, high throughput screening and toxicogenomics approaches have the potential to revolutionise how chemical substances, including nanomaterials, are assessed for regulatory and risk management purposes. A paradigm shift in toxicology using innovative techniques such as High Thoughput Screening (HTS) approaches, Toxicogenomics and High Content Analysis (HCA) is being established. With such approaches it is possible to identify underlying affected pathways (so called ‘toxicity pathways’). The challenge is to develop and demonstrate a mechanism-based understanding of toxicity, which will enable improved toxicity testing by identifying novel endpoints essential to tailor-made first tier hazard and risk assessment of novel and emerging materials.

Scope: Projects should enhance the understanding of the mechanisms underlying any observed adverse effects from engineered nanomaterials, and ultimately link the potential for such adverse effects to specific physical or chemical nano scale properties.

They should establish and demonstrate the basis for the development of appropriate tools to maximise read across (taxa and nano... ver más

Scope:Specific challenge: Systems biology, high throughput screening and toxicogenomics approaches have the potential to revolutionise how chemical substances, including nanomaterials, are assessed for regulatory and risk management purposes. A paradigm shift in toxicology using innovative techniques such as High Thoughput Screening (HTS) approaches, Toxicogenomics and High Content Analysis (HCA) is being established. With such approaches it is possible to identify underlying affected pathways (so called ‘toxicity pathways’). The challenge is to develop and demonstrate a mechanism-based understanding of toxicity, which will enable improved toxicity testing by identifying novel endpoints essential to tailor-made first tier hazard and risk assessment of novel and emerging materials.

Scope: Projects should enhance the understanding of the mechanisms underlying any observed adverse effects from engineered nanomaterials, and ultimately link the potential for such adverse effects to specific physical or chemical nano scale properties.

They should establish and demonstrate the basis for the development of appropriate tools to maximise read across (taxa and nano properties) and assess which tools or endpoints may not necessarily be applicable across the board. These approaches should aim to support the grouping of nanomaterials, to help in developing intelligent testing strategies and identifying "nanomaterials or properties of concern" that need to be tested more thoroughly.

Activities expected to focus on Technology Readiness Level 4.

The Commission considers that proposals requesting a contribution from the EU between EUR 4 and 8 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

•    New screening tools to enhance the efficiency of end-rate at which nanomaterial hazard profiling can be performed

•     Facilitate faster definition of nanomaterials toxicity mechanisms

•    Enable “safer by design” approaches, tailored to stakeholders’ needs (modellers, industry and regulators)

•   Data in a recognised and accessible database for use beyond the lifetime of the project

•   Provision of solutions to the long-term challenges of nanosafety and nanoregulation

Type of action: Research and Innovation Actions


Cross-cutting Priorities:International cooperation


ver menos

Temáticas Obligatorias del proyecto: Temática principal: Environment and health risks occupational medicin Nano-technology Nano-materials (production and properties) Toxicology

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Scope:Specific challenge: Systems biology, high throughput screening and toxicogenomics approaches have the potential to revolutionise how chemical substances, including nanomaterials, are assessed for regulatory and risk management purposes. A paradigm shift in toxicology using innovative techniques such as High Thoughput Screening (HTS) approaches, Toxicogenomics and High Content Analysis (HCA) is being established. With such approaches it is possible to identify underlying affected pathways (so called ‘toxicity pathways’). The challenge is to develop and demonstrate a mechanism-based understanding of toxicity, which will enable improved toxicity testing by identifying novel endpoints essential to tailor-made first tier hazard and risk assessment of novel and emerging materials. Scope:Specific challenge: Systems biology, high throughput screening and toxicogenomics approaches have the potential to revolutionise how chemical substances, including nanomaterials, are assessed for regulatory and risk management purposes. A paradigm shift in toxicology using innovative techniques such as High Thoughput Screening (HTS) approaches, Toxicogenomics and High Content Analysis (HCA) is being established. With such approaches it is possible to identify underlying affected pathways (so called ‘toxicity pathways’). The challenge is to develop and demonstrate a mechanism-based understanding of toxicity, which will enable improved toxicity testing by identifying novel endpoints essential to tailor-made first tier hazard and risk assessment of novel and emerging materials.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except that proposals will be ranked on the basis of individual scores for the Impact criterion before the Excellence criterion.
3.2 Guide to the submission and evaluation process
 
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of inform...
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except that proposals will be ranked on the basis of individual scores for the Impact criterion before the Excellence criterion.
3.2 Guide to the submission and evaluation process
 
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
 
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
Annotated Model Grant Agreement
 
Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Financial support to Third Parties – where a topic description foresees financial support to Third Parties, these provisions apply.
 
Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-NMP-2014-2015 Increasing the capacity to perform nano-safety assessment Scope:Specific challenge: Systems biology, high throughput screening and toxicogenomics approaches have the potential to revolutionise how c...
Sin info.
NMP-06-2015 Novel nanomatrices and nanocapsules
en consorcio: Scope:Specific challenge: Encapsulation technologies have been widely used for a long time in the pharmaceutical industry for drug delivery...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
NMP-12-2015 Biomaterials for treatment and prevention of Alzheimer's disease
en consorcio: Scope:Specific challenge: An estimated 7.3 million Europeans between 30 and 99 years of age suffered from different types of dementias in th...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
NMP-30-2015 Next generation tools for risk governance of nanomaterials
en consorcio: Scope:Specific challenge: The conventional risk assessment approach, i.e. deriving no-effect levels or limit values from dose-effect relatio...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
NMP-02-2015 Integration of novel nano materials into existing production lines
en consorcio: Scope:Specific challenge: Nanomaterials are intended to improve the performance of existing production technologies, and to give new functio...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
NMP-03-2015 Manufacturing and control of nanoporous materials
en consorcio: Scope:Specific challenge: There is a constantly growing interest in nanostructured porous materials, thanks to the many applications that ca...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de